Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rang in Aktien #29359
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Aktienkurs
$0.365
Zuletzt synchronisiert: 2025-08-01
Marktkapitalisierung
$21.54M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Elevation Oncology, Inc. (ELEV)

Kategorie

Kursverlauf für Elevation Oncology, Inc. (ELEV)
Höchster Schlusskurs: $0.37 am 2025-08-01

Niedrigster Schlusskurs: $12.36 am 2021-06-01
Kursverlauf der Aktie von Elevation Oncology, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2025 -40.93%
2024 21.56%
2023 -47.33%
2022 -81.61%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$543.58 39.11%
US
$1.02K 55.96%
NL
$149.47 435.54%
US
$117.42 -19.34%
AU
$755.62 8.92%
CH